Another upgrade on back of positive Breast treatment trial.
Analyst upgrade
H.C. Wainwright analyst Andrew Fein raised his price target for Seattle Genetics to $140 from $98 and reiterates a Buy rating on the shares. The "remarkable" HER2CLIMB topline results position Seattle Genetics "as a strong player" in the breast cancer space, Fein tells investors in a research note. He believes the "differentiating value" of tucatinib suggests a "strong" commercial outlook in the competitive HER2+ breast cancer landscape.
Company profile
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Analyst upgrade
H.C. Wainwright analyst Andrew Fein raised his price target for Seattle Genetics to $140 from $98 and reiterates a Buy rating on the shares. The "remarkable" HER2CLIMB topline results position Seattle Genetics "as a strong player" in the breast cancer space, Fein tells investors in a research note. He believes the "differentiating value" of tucatinib suggests a "strong" commercial outlook in the competitive HER2+ breast cancer landscape.
Company profile
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.